

UDC 616.33

https://doi.org/10.33619/2414-2948/56/20

## SOME INTENSE AND STANDARDIZED STOMACH CANCER DISEASE INDICATORS IN THE KYRGYZ REPUBLIC

©**Toigonbekov A.**, SPIN-code: 1951-1991, Dr. habil., National Center for Oncology and Hematology of the Ministry of Health of the Kyrgyz Republic, Bishkek, Kyrgyzstan

©**Akhunbaev S.**, M.D., International Higher School of Medicine,  
Bishkek, Kyrgyzstan, stal.ahunbaev@gmail.com

©**Umetov M.**, National Center for Oncology and Hematology of the Ministry of Health of the Kyrgyz Republic, Bishkek, Kyrgyzstan, maksatumetov@gmail.com

©**Tumanbaev A.**, National Center for Oncology and Hematology of the Ministry of Health of the Kyrgyz Republic, Bishkek, Kyrgyzstan

## НЕКОТОРЫЕ ИНТЕНСИВНЫЕ И СТАНДАРТИЗИРОВАННЫЕ ПОКАЗАТЕЛИ ЗАБОЛЕВАЕМОСТИ РАКОМ ЖЕЛУДКА В КИРГИЗСКОЙ РЕСПУБЛИКЕ

©**Тойгонбеков А. К.**, SPIN-код: 1951-1991, д-р мед. наук, Национальный центр онкологии и гематологии Министерства здравоохранения Кыргызской Республики,  
г. Бишкек, Кыргызстан

©**Ахунбаев С. М.**, канд. мед. наук, Международная высшая школа медицины,  
г. Бишкек, Кыргызстан, stal.ahunbaev@gmail.com

©**Уметов М. З.**, Национальный центр онкологии,  
г. Бишкек, Кыргызстан, maksatumetov@gmail.com

©**Туманбаев А. М.**, Национальный центр онкологии и гематологии Министерства здравоохранения Кыргызской Республики, г. Бишкек, Кыргызстан

*Abstract.* The article addresses issues oncological diseases in Kyrgyzstan. Incidence of gastric cancer in the Kyrgyz Republic is examined and the risks are analyzed. Statistics are given for regions and groups of residents. It is noted that, despite preventive measures, the number of diseases is growing. It is noted that in the Kyrgyz Republic the incidence among men is 2 times higher than among women. Stomach cancer morbidity rate increases with aging. The sickness peak is noted in age groups of 65–69. Supposedly, it is tied up to the etiological factors of risk.

*Аннотация.* В работе рассматриваются вопросы заболеваемости раком желудка в Кыргызской Республике и анализируются риски. Приведена статистика по областям и группам жителей. Отмечается, что, не смотря на профилактические меры, количество заболеваний растет. Отмечено, что в Кыргызской Республике заболеваемость среди мужчин в 2 раза выше, чем у женщин. Заболеваемость раком желудка увеличивается с возрастом. Пик болезни отмечен в возрастных группах от 65 до 69 лет. Высокий уровень заболеваемости выявлен также в возрастных группах 55–59 лет и 60–64 лет. Предположительно, это связано с этиологическими факторами риска.

*Keywords:* oncological disease, stomach cancer, cancer patients, incidence.

*Ключевые слова:* онкологическое заболевание, рак желудка, онкобольные, заболеваемость.



### *Scope of interest*

Stomach cancer (SC), regardless of decrease in the sickness rate, still remains one of the most commonly occurring diseases in the world with about 1 mln new registered cases every year. In most countries men's predisposition to the SC is 2 times higher in comparison to women's rate. The morbidity rate fluctuates within broad limits [7; 8]. Thus, according to the most recent data derived from MAIR pub. "Cancer in 5 continents" (vol.7), it's absolutely obvious that the SC morbidity rate is dependent on diet of population.

The availability in diet of enough vegetables and fruits, animal and vegetal proteins significantly reduces risks of SC.

The example of the USA is most prominent; within last 7 decades of healthy-diet promotion they have reduced the SC rate many times as less. Note, significant reduction of SC risks is found in Japanese emigrants permanently living in the USA, especially those of 2<sup>nd</sup> or 3<sup>rd</sup> generation. Russia is among countries with high SC morbidity rate, where new 50 thousand SC cases are registered every year [9].

However, there is a downward trend of SC sickness rate in Russia. Since 1990, the rate of morbidity has decreased for every 10 thousand people (16%) and now makes 48.2 per thousand people. In the oncologic diseases structure among men the SC goes 2<sup>nd</sup> (11.4%), among women goes 3<sup>rd</sup> (7.7%), and in the structure of death rate ranks 1<sup>st</sup> (16.3%) [1].

Due to the data presented above, the problem of epidemiology of the SC, its early diagnosis and prophylaxis have specific relevance. Russia goes 2<sup>nd</sup> for men and 3<sup>rd</sup> for women in the group of 45 countries under the level of mortality. Despite morbidity reduction during the last decade the mortality rate on 1<sup>st</sup> year of disease development is even increased. This is due to the proportion of patients with IV phase and reduction of oncologic aid to the population of Russia. [1; 2]. The highest rate of survival is registered in Japan — 53%, in other countries it's not higher than 15-20% [5].

The proportion of early detection of SC in Japan is highest as well and is up to a half of all cases, whereas in Europe, the USA and other countries it's no more than 20 %. Existing facts lead to a hypothesis that Japanese type of SC has distinct differences from SC in Europeans. However, further studies in molecular biology revealed fallacy of this hypothesis, and Japan is successful in survival with SC due to mass screening of the whole population and implementation of national programs of resistance to cancer [9].

Stomach cancer in Kyrgyz Republic goes 3<sup>rd</sup> in structure of oncologic morbidity and has 11,8% 000. SC is in the 1<sup>st</sup> place among males – 16,1%000, and 3<sup>rd</sup> place among females – 7,4%000. According to data on mortality rate, SC in Kyrgyz Republic ranks 1<sup>st</sup> (10,0%000). Early diagnosis indicators remain low (17,6%); neglect indicators (35,3%) and one-year mortality (81,7%) are high. [6]

### *Materials and Methodology*

We have conducted a research, including analysis of conditions of intense indicators of morbidity in Kyrgyzstan, taking 687 patients with SC in 2017.

All registered SC cases have additional information about general number and gender breakdown of the population of a region in question.

Besides, there is used information about number of adult population in different age-groups (15–19, 20–24, 25–29, 30–34 ... 80–84, 85 and >).

This matching is available after collection of data, including information about registration and hospitalization of patients with pancreas cancer. Age-indicators are calculated as a ratio of pancreas cancer cases to corresponding population number multiplied by 100 000. Standardized

morbidity indicators are defined by a direct method of morbidity indicators' standardization with the use of international standardized method.

This method of standard error determination under the direct method of standardization of morbidity indicators is called the method of Poisson. The ratio of 2 age-indicators of morbidity is defined as correlation of  $ASR_1$  to  $ASR_2$  (SRR - standardized rate ratio) and ensures understanding of relative risks of morbidity of one group of population in comparison to another.

### Results and Discussions

According to data of NCOH for 2017, the SC is in the first place in the structure of oncologic morbidity in Kyrgyzstan with number of — 10.0 to 100.000 people. Breast cancer (8.5) goes second, followed by cervical cancer (7.2). In comparison to 2001 the SC rate decreased from 13.6 [3] per 100.000 down to 10.0. Perhaps, this is tied to a low rate of early diagnostics and poor organization of registration of new oncologic cases.

Table 1

INCIDENCE OF MALIGNANT TUMORS OF GENERAL LOCALIZATIONS  
 IN POPULATION FOR 2016-2017 (to 100.000 people)

Regions	Years	Total	Esophagus	Stomach	Lungs	Breast	Cervix	Rectum	Prostate	Skin
Kyrgyz Republic	2016	3585	2,6	10,9	7,4	7,1	7,2	1,8	2,4	1,0
	2017	3501	2,4	10,0	6,8	8,5	7,2	1,5	1,0	1,1
Chui oblast	2016	777	2,5	13,3	12,0	16,3	15,2	2,5	6,5	4,4
	2017	706	2,4	11,1	11,7	10,5	12,9	3,0	2,2	2,1
Talas oblast	2016	151	3,5	15,0	7,5	4,7	9,5	0,3	0,7	0,7
	2017	155	3,5	10,5	7,7	5,5	11,7	1,1	0,3	0,3
Issyk-Kul oblast	2016	323	2,5	14,7	8,2	9,6	10,0	2,3	1,4	1,2
	2017	344	2,7	12,0	8,9	7,8	11,1	2,0	1,1	0,8
Naryn oblast	2016	238	3,2	19,6	12,5	9,4	10,1	2,5	1,4	2,5
	2017	216	3,8	15,5	7,0	7,2	20,8	1,4	1,0	1,4
Osh oblast	2016	785	5,3	12,9	7,7	4,1	5,5	1,8	0,7	0,7
	2017	689	3,3	10,1	6,3	5,4	4,1	1,1	0,6	1,4
Jalal-Abad oblast	2016	488	1,9	9,1	4,8	6,0	6,0	0,7	0,5	0,6
	2017	537	2,6	9,5	4,7	6,9	6,3	0,8	0,5	0,9
Batken oblast	2016	184	2,0	6,0	3,2	3,2	6,9	0,8	-	1,2
	2017	162	2,1	5,5	3,5	4,0	5,2	1,1	-	0,7




Figure 1. Age morbidity indicators for stomach cancer in 2017.

The Figure 1 shows that the SC morbidity age indicators have highest numbers at the age of 65-69 (116 to 100.000). Another essential fact is the high morbidity rate is detected at ages 55–59 and 60–64 (48,6 – 58 to 100.000 resp.).

Table 2 shows that the standardized age indicator is 16.5 to 100.000 of population, while the standardized international indicator is 13.8 to 100.000.

Table 2

**MORBIDITY INDICATORS (BOTH GENDERS) OF STOMACH CANCER STANDARDIZED BY AGE IN THE KYRGYZ REPUBLIC FOR 2017**

<i>Age index (i)</i>	<i>Age group</i>	<i>Number of registered cases (ri)</i>	<i>Age indicator for adults (ri/ni)</i>	<i>World's standard population (wi)</i>	<i>Standardized indicators for world's standard population</i>
1	0-4	0	0	12000	
2	5-9	0	0	10000	
3	10-14	0	0	9000	
4	15-19	1	0,200517737	9000	
5	20-24	0	0	8000	
6	25-29	8	1,376005559	8000	
7	30-34	18	3,682201466	6000	
8	35-39	29	7,551985	6000	
9	40-44	46	13,56360002	6000	
10	45-49	95	30,00811799	6000	
11	50-54	110	37,71747554	5000	
12	55-59	126	48,60079844	4000	
13	60-64	100	57,98916762	4000	
14	65-69	132	116,412382	3000	
15	70-74	16	34,18949528	2000	
16	75-79	5	8,665511265	1000	
17	80-84	1	3,160656152	500	
18	85+	0	0	500	
<i>Total:</i>		687	16,47154164	100000	13,84457349

Table 3

**AGE INDICATORS FOR STOMACH CANCER (MEN) IN KYRGYZSTAN IN 2017**

<i>Age index (i)</i>	<i>Age group</i>	<i>Number of registered cases (ri)</i>	<i>Number of population (ni)</i>	<i>Age indicator (ri/ni)</i>
1	0-4	0	400132	0
2	5-9	0	337249	0
3	10-14	0	270624	0
4	15-19	0	253845	0
5	20-24	1	287184	0,4
6	25-29	0	292326	0
7	30-34	6	245586	2,4
8	35-39	15	192495	7,8
9	40-44	19	166054	11,4
10	45-49	32	153212	20,9
11	50-54	77	138110	55,8
12	55-59	81	120612	67,2
13	60-64	82	76677	107

Age index (i)	Age group	Number of registered cases (ri)	Number of population (ni)	Age indicator (ri/ni)
14	65-69	59	47679	123,7
15	70-74	73	18987	384,5
16	75-79	12	21733	55,2
17	80-84	4	10980	36,4
18	85+	1	9025	11,1
<i>Total:</i>		462	2034505	22,7

Table 3 shows that men have relatively high intense indicator of 22.7 to 100.000, whereas women (Table 4) have intense indicator of 10.5.

Table 4

AGE INDICATORS FOR STOMACH CANCER (WOMEN) IN KYRGYZSTAN IN 2017

Age index (i)	Age group	Number of registered cases (ri)	Number of population (ni)	By-age indicators (ri/ni)
1	0-4	0	378270	0
2	5-9	0	322832	0
3	10-14	0	260263	0
4	15-19	0	244864	0
5	20-24	0	276386	0
6	25-29	0	289067	0
7	30-34	2	243252	0,8
8	35-39	3	191510	1,6
9	40-44	10	173089	5,8
10	45-49	14	163369	8,6
11	50-54	18	153532	11,7
12	55-59	29	138643	20,9
13	60-64	44	95769	45,9
14	65-69	41	65711	62,4
15	70-74	59	27811	212
16	75-79	4	35967	11,1
17	80-84	1	20659	4,8
18	85+	0	16696	0
<i>Total:</i>		225	2136325	10,5

Comparing intense indicators, morbidity rate in men is 2 times higher than in women almost in all age groups. (Figure 2).

Stomach cancer morbidity rate in Kyrgyzstan is high and roughly it is 16.5 per 100.000 in 2017, whereas in the international area it is only 13.8 to 100.000. In the Kyrgyz Republic men's morbidity rate is 2 times higher than women's — 22.7 and 10.5 per 100.000 resp.

Stomach cancer morbidity rate increases with aging. The sickness peak is noted in age groups of 65-69 (116 to 100.000). However, high morbidity rate is detected in age groups of 55-59 and 60-64 as well (48.6 – 58 per 100.000 resp.). Supposedly, it is tied up to etiological factors of risk.




Figure 2. Relative characteristic of SC age morbidity indicators in both genders

#### References:

1. Dolgushin, B. I., Virshke, E. R., Kosirev, V. Y., Trofimov, I. A., Kukushkin, A. V., Cherkasov, V. A., ... & Shishkina, N. A. (2010). Transcatheter Arterial Chemoembolization with Doxorubicin Loaded Microspheres in Management of Nonresectable Hepatocellular Carcinoma (Long term results). *Int. J. Cancer*, 127(12).
2. Davydov, M. I. (2000). Ter Ovanesov MD Sovremennaya strategiya khirurgicheskogo lecheniya raka zheludka. *Sovremennaya onkologiya*, 2(1), 4-12. (in Russian).
3. Zaridze, D. G. (2000). Epidemiology and etiology of malignant tumors. *Carcinogenesis*, 21-56.
4. Bondarev, A. V., Efetov, S. V., Oleksenko, V. V., Cheripko, O. N., Dzhemilev, T. R., & Aliev, K. A. (2010). Khirurgicheskoe lecheniya rannego raka pochki. *Tavrisheskii mediko-biologicheskii vestnik*, (16). 262-270. (in Russian).
5. Samsonov, D. V. (2010). Prognosticheskie faktory i rezul'taty khirurgicheskogo lecheniya mestnorasprostrannogo raka zheludka: avtoref. dis. ... kand. med. nauk. St. Petersburg. (in Russian).
6. Aidarbekova, A. A., Sulaimanova, A. A., Soodonbekov, E. T., Minenkov, G. O., & Turgunbaev, U. A. (2017). Sovershenstvovanie sistemy okazaniya spetsializirovannoi onkologicheskoi pomoshchi naseleniyu Kyrgyzskoi respublikii. *Problemy Nauki*, 17(99). 92-96. (in Russian).
7. Merabishvili, V. M. (2001). Rak zheludka: epidemiologiya, profilaktika, otsenka effektivnosti lecheniya na populyatsionnom urovne. *Prakticheskaya onkologiya*, 3(7), 3-8. (in Russian).
8. Chissov, V. I., Starinskii, V. V., & Petrova, G. V. (red.). (2012). Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2011 godu. Moscow. (in Russian).
9. Gotoda, T., Yanagisawa, A., Sasako, M., Ono, H., Nakanishi, Y., Shimoda, T., & Kato, Y. (2000). Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. *Gastric cancer*, 3(4), 219-225. <https://doi.org/10.1007/PL00011720>

*Список литературы:*

1. Dolgushin B. I., Virshke E. R., Kosirev V. Y., Trofimov I. A., Kukushkin A. V., Cherkasov V. A., ... Shishkina N. A. Transcatheter Arterial Chemoembolization with Doxorubicin Loaded Microspheres in Management of Nonresectable Hepatocellular Carcinoma (Long term results) // Int. J. Cancer. 2010. V. 127. №12.
2. Давыдов М. И. Тер Ованесов М. Д. Современная стратегия хирургического лечения рака желудка // Современная онкология. 2000. Т. 2. №1. С. 4-12.
3. Zaridze D. G. Epidemiology and etiology of malignant tumors // Carcinogenesis. 2000. P. 21-56.
4. Бондарев А. В., Ефетов С. В., Олексенко В. В., Черипко О. Н., Джемилев Т. Р., Алиев К. А. Хирургическое лечения раннего рака почки // Таврический медико-биологический вестник. 2010. №16. С. 262-270.
5. Самсонов Д. В. Прогностические факторы и результаты хирургического лечения местнораспространенного рака желудка: автореф. дис. ... канд. мед. наук. СПб., 2010. 22 с.
6. Айдарбекова А. А., Сулайманова А. А., Соодонбеков Э. Т., Миненков Г. О., Тургунбаев У. А. Совершенствование системы оказания специализированной онкологической помощи населению Кыргызской республики // Проблемы Науки. 2017. №17(99). С. 92-96.
7. Мерабишвили В. М. Рак желудка: эпидемиология, профилактика, оценка эффективности лечения на популяционном уровне // Практическая онкология. 2001. №3(7). С. 3-8.
8. Чиссов В. И., Старинский В. В., Петрова Г. В. (ред.). Состояние онкологической помощи населению России в 2011 году. М., 2012. 240 с.
9. Gotoda T., Yanagisawa A., Sasako M., Ono H., Nakanishi Y., Shimoda T., Kato Y. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers // Gastric cancer. 2000. V. 3. №4. P. 219-225. <https://doi.org/10.1007/PL00011720>

*Работа поступила  
в редакцию 09.06.2020 г.*

*Принята к публикации  
13.06.2020 г.*

*Ссылка для цитирования:*

Toigonbekov A., Akhunbaev S., Umetov M., Tumanbaev A. Some Intense and Standardized Stomach Cancer Disease Indicators in the Kyrgyz Republic // Бюллетень науки и практики. 2020. Т. 6. №7. С. 169-175. <https://doi.org/10.33619/2414-2948/56/20>

*Cite as (APA):*

Toigonbekov, A., Akhunbaev, S., Umetov, M., & Tumanbaev, A. (2020). Some Intense and Standardized Stomach Cancer Disease Indicators in the Kyrgyz Republic. *Bulletin of Science and Practice*, 6(7), 169-175. <https://doi.org/10.33619/2414-2948/56/20>

